Xcout Intel
AMICUS THERAPEUTICS INC competitors & alternatives
The 12 closest competitors and alternatives to AMICUS THERAPEUTICS INC among biotech companies — ranked by similarity to what AMICUS THERAPEUTICS INC actually does, not by market-cap band.
Subscribe to see AMICUS THERAPEUTICS INC’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About AMICUS THERAPEUTICS INC
Amicus Therapeutics, Inc. is an American biopharmaceutical company focused on discovering and delivering advanced therapies for rare diseases. The company is publicly traded on Nasdaq and maintains its global corporate headquarters in Princeton, New Jersey.
AMICUS THERAPEUTICS INC at a glance
AMICUS THERAPEUTICS INC is a biotech company headquartered in United States. It has raised at least $234.6M across the 3 funding rounds on record. Its most recent funding round raised $30M in October 2023. Xcout tracks 2 named people at AMICUS THERAPEUTICS INC, including Alexander Hardy (President and Chief Executive Officer).
AMICUS THERAPEUTICS INC leadership
- Alexander HardyPresident and Chief Executive Officer
- Jean-Jacques BienaiméChief Executive Officer
AMICUS THERAPEUTICS INC funding rounds
At least $234.6M raised across the 3 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $30M | — | |
| SEC Form D filing | $199.9M | — | |
| SEC Form D filing | $4.7M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent AMICUS THERAPEUTICS INC news
Top 12 AMICUS THERAPEUTICS INC competitors
Ranked by semantic similarity — how close each company is to AMICUS THERAPEUTICS INC by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
Amicus Therapeutics, a subsidiary of BioMarin Pharmaceutical Inc., is a biotechnology company that researches and delivers medicines for individuals living with genetically defined rare diseases. The company provides patient advocacy and support services alongside its clinical development pipeline.
Biotechnology
Applied Therapeutics, Inc. is a biopharmaceutical company headquartered in New York City, focused on developing novel product candidates targeted at disease targets involving enzyme and metabolic pathways.
Biotechnology
Travere Therapeutics is a biopharmaceutical company headquartered in San Diego, California, focused on identifying, developing, and delivering life-changing therapies for people living with rare diseases.
Similar biotech company
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications. Among its commercialized products, PTC Therapeutics provides Translarna and Emflaza, offering therapeutic options for Duchenne muscular dystrophy patients in the European Economic Area and the United States. Translarna also addresses nonsense mutation Duchenne muscular dystrophy in Brazil and Russia. The company additionally commercializes Tegsedi and Waylivra for various rare conditions throughout Latin America and the Caribbean. Furthermore, in Brazil, PTC Therapeutics distributes Evrysdi as a treatment for spinal muscular atrophy (SMA) in patients aged two months and older. Leveraging its proprietary splicing platform, the company is also actively developing PTC518, a promising therapeutic candidate aimed at treating Huntington's disease. To bolster its research and development capabilities, PTC Therapeutics has established strategic collaborations, including partnerships with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation, focusing on advancing drug discovery and development research, particularly in regenerative medicine. Additionally, it collaborates with Akcea Therapeutics, Inc. for the commercialization of Tegsedi and Waylivra in the Latin America and Caribbean region. Established in 1998, PTC Therapeutics, Inc. maintains its corporate headquarters in South Plainfield, New Jersey.
Similar biotech company
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
Similar biotech company
Orchard Therapeutics plc is a biopharmaceutical company with operations including a U.S. headquarters located in Boston, Massachusetts.
Similar biotech company
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Biotechnology
Ayala Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Monmouth Junction, New Jersey. The company focuses on developing targeted therapeutics for rare tumors and aggressive cancers. It engages in clinical research and asset management within the biotechnology and pharmaceutical sector.
Biotechnology
Ambros Therapeutics is a clinical-stage biotechnology company headquartered in Irvine, California, focused on the development of innovative therapeutics.
Similar biotech company
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Biotechnology
Theranexus (THX Pharma) is a clinical-stage biopharmaceutical company that develops innovative therapeutic solutions for patients suffering from rare neurological diseases such as Batten disease, Niemann-Pick type C, and Gaucher disease. The company utilizes scientific research and antisense oligonucleotides to create targeted drug candidates addressing significant unmet medical needs.
Biotechnology
Sobi - Swedish Orphan Biovitrum AB is an international biopharmaceutical company dedicated to treatments in the areas of haematology, immunology and specialty care. Headquartered in Stockholm, Sweden, with major hubs in Basel, Switzerland, and Waltham, USA. Sobi has a global presence in approximately 30 countries and provides medicines to patients in many more around world.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of AMICUS THERAPEUTICS INC and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for AMICUS THERAPEUTICS INCand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →